XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.3
Organization and Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2024
Organization and Summary of Significant Accounting Policies [Abstract]  
Schedule of Consolidated Balance Sheets The Company’s consolidated balance sheets included the following assets and liabilities from its VIE:
   September 30,
   December 31,
 
   2024   2023 
Cash  $147,971   $5,862 
Total assets  $179,988   $5,862 
           
Due to the Company and Dragon (eliminates in consolidation)  $4,858,516   $1,023,746 
Total liabilities  $4,875,738   $1,023,746 
Schedule of Financial Assets and Liabilities Measured at Fair Value The following table represents the Company’s fair value hierarchy of its financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2024 and December 31, 2023.
   September 30, 2024   December 31, 2023 
Description  Level 1   Level 2   Level 3   Level 1   Level 2   Level 3 
Short-term investments  $3,919,697   $
-
   $
-
   $5,236,781   $
-
   $
-
 
Schedule of Research and Development Expense In connection with this asset acquisition, the Company recorded research and development expense of $166,667 since the Company is still in the development stage and spends most of its time and efforts planning, raising capital, and performing research and development and accordingly, the recoverability of the cost was not certain. Research and development expense was calculated as follows:
   Amount 
Fair value of 8,000,000 shares Dragon shares transferred based on recent sales of Dragon shares at $0.30 per share  $2,400,000 
      
Less: gain recognized as difference between fair value of 8,000,000 shares calculated above and allocated costs of investment in Dragon and included in research and development   (2,233,333)
      
Research and development expense recorded, net  $166,667 
Schedule of Computation Diluted Shares Outstanding The following were excluded from the computation of diluted shares outstanding as they would have had an anti-dilutive impact on the Company’s net loss.
   September 30, 
   2024   2023 
Common stock equivalents:        
Common stock warrants   67,385    67,385 
Common stock options   140,570    166,420 
Total   207,955    233,805